Oxybutynin is an anticholinergic drug with an emerging role in the treatment of hyperhidrosis. Several recent studies have documented that it is effective both in focal and generalized hyperhidrosis and shows universally good response among different groups of patients regardless of age, gender, and weight. The most common adverse event is dry mouth reported by almost all patients treated. The way this might affect long-term compliance and tolerability should be better investigated in the future.

Keywords:
Botulinum toxin, Children, Hyperhidrosis, Sweat glands, Xerostomia
1.
Atkins JL, Butler PE: Hyperhidrosis: a review of current management. Plast Reconstr Surg 2002;110:222-228.
2.
Wolosker N, de Campos JR, Kauffman P, de Oliveira LA, Munia MA, Jatene FB: Evaluation of quality of life over time among 453 patients with hyperhidrosis submitted to endoscopic thoracic sympathectomy. J Vasc Surg 2012;55:154-156.
3.
Stashak AB, Brewer JD: Management of hyperhidrosis. Clin Cosmet Investig Dermatol 2014;7:285-299.
4.
Fujimoto T, Kawahara K, Yokozeki H: Epidemiological study and considerations of primary focal hyperhidrosis in Japan: from questionnaire analysis. J Dermatol 2013;40:886-890.
5.
Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I: Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology 2013;227:10-13.
6.
Stefaniak T, Tomaszewski KA, Proczko-Markuszewska M, Idestal A, Royton A, Abi-Khalil C: Is subjective hyperhidrosis assessment sufficient enough? Prevalence of hyperhidrosis among young Polish adults. J Dermatol 2013;40:819-823.
7.
Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, Smith KC, Storwick G: A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 2007;33:908-923.
8.
Hölzle E: Topical pharmacological treatment. Curr Probl Dermatol 2002;30:30-43.
9.
Hölzle E, Braun-Falco O: Structural changes in axillary eccrine glands following long-term treatment with aluminium chloride hexahydrate solution. Br J Dermatol 1984;110:399-403.
10.
White JW Jr: Treatment of primary hyperhidrosis. Mayo Clin Proc 1986;61:951-956.
11.
Shaw JE, Abbott CA, Tindle K, Hollis S, Boulton AJ: A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating. Diabetologia 1997;40:299-301.
12.
Benson RA, Palin R, Holt PJ, Loftus IM: Diagnosis and management of hyperhidrosis. BMJ 2013;347:f6800.
13.
Prasad A, Ali M, Kaul S: Endoscopic thoracic sympathectomy for primary palmar hyperhidrosis. Surg Endosc 2010;24:1952-1957.
14.
Tupker RA, Harmsze AM, Deneer VHM: Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol 2006;142:1065-1066.
15.
de Moura Júnior NB, das-Neves-Pereira JC, de Oliveira FRG, Jatene FB, Parra ER, Capelozzi VL, et al: Expression of acetylcholine and its receptor in human sympathetic ganglia in primary hyperhidrosis. Ann Thorac Surg 2013;95:465-470.
16.
Ouslander J, et al: Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988;140:47-50.
17.
Hughes KM, et al: Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992;22:859-869.
18.
Yarker Y, et al: Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-262.
19.
Yong C, et al: Effect of food on the pharmacokinetics of oxybutynin in normal subjects. Pharm Res 1991;8(suppl):S-320.
20.
LeWitt P: Hyperhidrosis and hypothermia responsive to oxybutynin. Neurology 1988;38:506-507.
21.
Wolosker N, de Campos JRM, Kauffman P, Neves S, Munia MA, Jatene FB, et al: The use of oxybutynin for treating axillary hyperhidrosis. Ann Vasc Surg 2011;25:1057-1062.
22.
Wolosker N, Campos JRM de, Kauffman P, Munia MA, Neves S, Jatene FB, et al: The use of oxybutynin for treating facial hyperhidrosis. An Bras Dermatol 2011;86:451-456.
23.
Wolosker N, Campos JR, Kauffman P, Neves S, Yazbek G, Jatene FB, et al: An alternative to treat palmar hyperhidrosis: use of oxybutynin. Clin Auton Res 2011;21:389-393.
24.
Wolosker N, de Campos JRM, Kauffman P, Yazbek G, Neves S, Puech-Leão P: Use of oxybutynin for treating plantar hyperhidrosis. Int J Dermatol 2013;52:620-623.
25.
Wolosker N, de Campos JRM, Kauffman P, Puech-Leão P: A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg 2012;55:1696-1700.
26.
Wolosker N, Teivelis MP, Krutman M, de Paula RP, Kauffman P, de Campos JR, Puech-Leão P: Long-term results of the use of oxybutynin for the treatment of axillary hyperhidrosis. Ann Vasc Surg 2014;28:1106-1112.
27.
Costa Ada S Jr, Leão LE, Succi JE, Perfeito JA, Filho Castelo A, Rymkiewicz E, Filho Aurelio Marchetti M: Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy. Clinics (Sao Paulo) 2014;69:101-105.
28.
Teivelis MP, Wolosker N, Krutman M, Kauffman P, de Campos JR, Puech-Leão P: Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin. Clinics (Sao Paulo) 2014;69:608-614.
29.
Wolosker N, Schvartsman C, Krutman M, Campbell TP, Kauffman P, de Campos JR, Puech-Leão P: Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old. Pediatr Dermatol 2014;31:48-53.
30.
Lacerf JM, Reitz C, de Chasteigner A: Evaluation of discomfort and complications in a population of 18,102 overweight or obese patients (in French). Presse Med 2002;15:689-695.
31.
Wolosker N, Krutman M, Kauffman P, Paula RP, Campos JR, Puech-Leão P: Effectiveness of oxybutynin for treatment of hyperhidrosis in overweight and obese patients. Rev Assoc Med Bras 2013;59:143-147.
32.
Wolosker N, Krutman M, Teivelis MP, de Paula RP, Kauffman P, de Campos JR, Puech-Leão P: Analysis of oxybutynin treatment for hyperhidrosis in patients aged over 40 years. Einstein (Sao Paulo) 2014;12:42-47.
33.
Wolosker N, Krutman M, Campdell TP, Kauffman P, Campos JR, Puech-Leão P: Oxybutynin treatment for hyperhidrosis: a comparative analysis between genders. Einstein (Sao Paulo) 2012;10:405-408.
34.
Kim WO, Kil HK, Yoon KB, Yoo JH: Treatment of generalized hyperhidrosis with oxybutynin in postmenopausal patients. Acta Derm Venereol 2010;90:291-293.
35.
Try C, Messikh R, Elkhyat A, Aubin F, Humbert RP: Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis. Rev Med Liege 2012;67:520-526.
36.
Amir M, Arish A, Weinstein Y, Pfeffer M, Levy Y: Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results. Isr J Psychiatry Relat Sci 2000;37:25-31.
37.
Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z: Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014;65:755-765.
38.
Wolosker N, Teivelis MP, Krutman M, de Paula RP, de Campos JR, Kauffman P, Puech-Leão P: Long-term results of oxybutynin treatment for palmar hyperhidrosis. Clin Auton Res 2014;24:297-303.
39.
Maillard H, Fenot M, Bara C, Célérier P: Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis. Ann Dermatol Venereol 2011;138:652-656.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.